Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Siegmund

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Diabetes Research and Clinical Practice|April 3, 2020
Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetesThorsten Siegmund, Francisco Javier Ampudia-Blasco, Oliver Schnell
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2020
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 UpdateMarkolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, et al.
Journal of Diabetes Science and Technology|March 22, 2017
Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic TargetThorsten Siegmund, Lutz Heinemann, Ralf Kolassa, et al.
Journal of Diabetes Science and Technology|November 14, 2019
Clinical Recommendations for the Use of the Ambulatory Glucose Profile in Diabetes CareJens Kröger, Andreas Reichel, Thorsten Siegmund, et al.
Deutsche Medizinische Wochenschrift (1946)|January 13, 2015
[Obesity: causes and consequences]Alexandra Willms, Thorsten Siegmund, Petra-Maria Schumm-Draeger
Journal of Diabetes Science and Technology|April 19, 2018
Response to "Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: A Reply"Thorsten Siegmund, Lutz Heinemann, Ralph Kolassa, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|June 7, 2005
(Postprandial) hyperglycemia is (cardio)vascular disease: are new concepts for diagnosis and treatment required?Helene von Bibra, Thorsten Siegmund, Petra-Maria Schumm-Draeger
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2021
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT StudyMartin Pfohl, Jochen Seufert, Anja Borck, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 29, 2021
A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting GlucoseStephan Kress, Anja Borck, Ariel Zisman, et al.
Vascular Health and Risk Management|November 26, 2015
Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational studyMartin Pfohl, Thorsten Siegmund, Stefan Pscherer, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Diabetes Research and Clinical Practice|April 3, 2020
Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetesThorsten Siegmund, Francisco Javier Ampudia-Blasco, Oliver Schnell
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2020
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 UpdateMarkolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, et al.
Journal of Diabetes Science and Technology|March 22, 2017
Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic TargetThorsten Siegmund, Lutz Heinemann, Ralf Kolassa, et al.
Journal of Diabetes Science and Technology|November 14, 2019
Clinical Recommendations for the Use of the Ambulatory Glucose Profile in Diabetes CareJens Kröger, Andreas Reichel, Thorsten Siegmund, et al.
Deutsche Medizinische Wochenschrift (1946)|January 13, 2015
[Obesity: causes and consequences]Alexandra Willms, Thorsten Siegmund, Petra-Maria Schumm-Draeger
Journal of Diabetes Science and Technology|April 19, 2018
Response to "Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: A Reply"Thorsten Siegmund, Lutz Heinemann, Ralph Kolassa, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|June 7, 2005
(Postprandial) hyperglycemia is (cardio)vascular disease: are new concepts for diagnosis and treatment required?Helene von Bibra, Thorsten Siegmund, Petra-Maria Schumm-Draeger
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2021
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT StudyMartin Pfohl, Jochen Seufert, Anja Borck, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 29, 2021
A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting GlucoseStephan Kress, Anja Borck, Ariel Zisman, et al.
Vascular Health and Risk Management|November 26, 2015
Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational studyMartin Pfohl, Thorsten Siegmund, Stefan Pscherer, et al.
Pageof 5